Currently recruiting is a clinical trial Synergy-201 (NCT06228053), investigating SX-682, an inhibitor of CXCR1/2, in combination with enzalutamide in men with abiraterone-resistant metastatic castration-resistant PCa. This evidence concerns the gene CXCR1 and posterior cortical atrophy.